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Frequency of GNAS R201H 
substitution mutation in 
polyostotic fibrous dysplasia: 
Pyrosequencing analysis in 
tissue samples with or without 
decalcification
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Guanine nucleotide-binding protein/α-subunit (GNAS) mutations are involved in fibrous dysplasia (FD) 
pathogenesis. Here, we analyzed GNAS mutations in FD which were performed by pyrosequencing 
DNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue. The mutation detection rate was 
determined in FD specimens with and without decalcification. GNAS mutation was identified in 28 cases 
out of 87 FDs (32.18%) [p.R201C (N = 14) and p.R201H (N = 14)]. GNAS mutation was more likely to 
occur in polyostotic FD (7/28, 25.0%); FD without GNAS mutation was mostly monostotic form (56/59, 
94.9%, P = 0.011). The G > A (R201H) mutation was more frequent in polyostotic FD (6/14 patients, 
42.9%) than the C > T (R201C) mutation (1/14, 7.1%) (P = 0.077). We divided the FD cases into two 
subgroups: tissue specimens that were not decalcified (N = 35, 40.2%), and tissue specimens that were 
decalcified (N = 52, 59.8%). GNAS mutation was more frequently identified in FD specimens that were 
not subjected to decalcification (23/35, 65.7%) than in FD specimens that were decalcified (5/52, 9.6%) 
(P = 0.001). In conclusion, mutation analysis of GNAS by pyrosequencing has diagnostic value in FFPE 
tissue of patients with FD, especially in specimens that were not decalcified. The R201H substitution 
mutation of GNAS may be involved in the pathogenesis of polyostotic FD.
Fibrous dysplasia (FD) is a frequently encountered benign fibro-osseous lesion. FD is histologically characterized 
by fibrous tissue with bland-looking fibroblasts, irregularly shaped woven bone, and no osteoblastic rimming. 
FD can be involved in one site (monostotic disease) or several sites (polyostotic disease) of any bone. In approxi-
mately 5% of all cases, polyostotic disease may be associated with McCune-Albright syndrome1. Monostotic and 
polyostotic FD, McCune-Albright syndrome, and soft tissue myxoma with FD all result from somatic mutation of 
the same guanine nucleotide-binding protein/a-subunit (GNAS) gene2–4.
GNAS is located on chromosome 20q13.3, which encodes the α-subunit of the heterotrimeric G (Gsα) pro-
tein complex4–6. GNAS mutations induce the activation of G-protein a-subunit and cause FD, also known as 
McCune-Albright syndrome5–7. FD is thought to be predominantly caused by two mutations in exon 8 of the 
GNAS gene8. These mutations are substitutions in codon 201, which lead to the replacement of arginine 201 with 
histidine (R201H) or cysteine (R201C). Substitution of arginine 201 with serine (R201S)9, leucine (R201L)10, 11, 
and glycine (R201G) have been reported in rare cases12. One study reported a point mutation at codon 227 (glu-
tamine) in exon 9 of GNAS, which led to replacement with leucine (Q227L)13.
Several studies showed that no GNAS mutations were detected in all other benign fibro-osseous lesions, and 
suggested that mutation analysis of GNAS is a reliable and valuable diagnostic tool for FD. A meta-analysis of 
203 patients with FD reported the positive detection of GNAS mutation in 71.9% of the patients14. However, 
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the detection rate in subsequent studies varied from 45–95% due to tissue mosaicism and sensitivity of the 
technique15–19.
Several methods can be used to detect GNAS mutations in paraffin-embedded tissues or frozen samples, 
including Sanger direct sequencing14, 17, allele-specific PCR20, PCR with mutation-specific restriction enzyme 
digestion13, and coamplification at lower denaturation temperature PCR (COLD-PCR)4. Recently, Liang et al. 
reported a detection sensitivity of GNAS mutation as high as 95% using next-generation pyrosequencing19. 
They isolated DNA from undercalcified, formalin-fixed, methylmethacrylate-embedded tissue. However, most 
other studies used tissue specimens that had been subjected to various decalcification methods before preparing 
formalin-fixed paraffin-embedded (FFPE) FD tissue samples. Calcified tissues were treated with strong acid for 
decalcification before fixation and embedding. This harsh treatment may affect DNA integrity, and reduce the 
quantity and quality of DNA for amplification and sequencing21.
In this study, we evaluated the effect of tissue decalcification on the diagnosis of FD by pyrosequencing for 
GNAS mutations. We selected FFPE specimens of patients with FD according to whether they had undergone 
decalcification or not, and used these samples to detect GNAS mutations. We also analyzed clinicopathological 
features according to GNAS mutation status.
Results
Clinical and pathological features. The clinical features of 87 patients with FD are presented in 
Supplementary Table 1. The male-to-female ratio of patients with FD was approximately 1:1 (43 males and 44 
females). The median onset age was 31.02 years (range, 1–85 years). A total of 34 patients had FD located at 
craniofacial sites (34/87, 39.1%), and the remainder were located at extracraniofacial sites (53/87, 60.9%). Ten 
patients had multiple bone lesions at FD diagnosis, which radiologically suggested polyostotic FD. One of these 
10 patients was diagnosed with Albright-McCune syndrome. Tissue samples were not decalcified before formalin 
fixation for 35 patients; the tissues samples of the remaining 52 patients were decalcified before formalin fixation.
Histological examination indicated that most FD lesions contained varying proportions of fibrous tissue with 
irregular, curvilinear, and trabeculae of woven bone without osteoblastic rimming (Fig. 1). Some samples dis-
played aggregation of foamy histiocytes and cystic change. Benign cartilaginous differentiation was observed in 
one sample.
GNAS mutation in fibrous dysplasia. We performed pyrosequencing and detected GNAS mutations in 
28 out of 87 patients with FD (32.2%, Table 1). Fourteen cases had the R201H mutation, and 14 cases had the 
R201C mutation (Fig. 2). We divided the FD patients into two groups, FD with GNAS mutation and FD without 
GNAS mutation, and compared clinical features in the two groups (Table 1). The results showed that polyostotic 
disease was observed more frequently in FD cases with GNAS mutation (7/28, 25.0%) than in FD without GNAS 
mutation (3/59, 5.1%, P = 0.011). However, there were no significant differences between the two groups with 
respect to gender, age at diagnosis, or lesion site.
GNAS mutation rate in fibrous dysplasia specimens with or without decalcification. The 
observed GNAS mutation rate in tissue samples from patients with FD (32.2%) was remarkably lower than that 
reported by a previous study (95%)19. Both studies used the same next-generation sequencing method, a pyrose-
quencing. Therefore, we hypothesized that mutation rates are affected by decalcification, and compared mutation 
rates according to whether or not the FD tissue samples were decalcified (Table 2). The observed GNAS mutation 
rate was much lower in FD tissue specimens that had been subjected to decalcification (5/52, 9.6%) than in FD 
specimens without decalcification (23/35, 65.7%, P = 0.001).
To verify the effect of tissue decalcification on the detection rate of GNAS mutations by pyrosequencing, we 
divided tissue specimens from 15 FD patients into two parts: one part of each specimen was decalcified, and the 
other part was not decalcified. Subsequent tissue processing, PCR, and pyrosequencing reactions were the same 
for both tissue samples. Table 2 compares the observed GNAS mutation rates in these two tissues (decalcified 
or not) for the 15 FD patients. Consistent with the previous experiment, the observed GNAS mutation rates in 
decalcified tissue specimens were lower (2/15, 13.3%) that those in undercalcified tissue specimens (9/15, 60.0%, 
P = 0.021). These combined results indicate that GNAS mutation was not detected in 7 FD patients when the 
source of DNA for diagnostic pyrosequencing reactions was derived from decalcified tissue specimens.
Clinical features of fibrous dysplasia according to GNAS mutation type. We detected GNAS muta-
tion in 28 out of 87 FD lesions (Table 1). Fourteen of these patients had C > T substitution mutations (R201C) 
and the other 14 patients had G > A substitution mutations (R201H). Other rare mutations were not identified.
The R201H mutation occurred more frequently in polyostotic FD, whereas the R201C mutation occurred 
more frequently in monostotic FD (P = 0.077). There were no significant differences in gender, age at diagnosis, 
or lesion site between patients with R201H and R201C mutations in GNAS leading to FD.
Discussion
GNAS encodes a subunit of the stimulatory cAMP pathway-associated G-protein, Gsα. Activating or 
gain-of-function GNAS mutations in osteoblastic cells result in adenylate cyclase activation and constitutive 
elevation of intracellular cyclic adenosine monophosphate (cAMP). Consequently, mutated osteoblastic cells 
undergo increased cell proliferation and reduced cell differentiation, resulting in overproduction of disorganized 
fibrotic bone matrix. This process is responsible for the development of FD, which may also present as a feature of 
McCune-Albright syndrome (endocrine diseases or Café au lait macules occurs in addition to FD)22–25.
The diagnosis of FD usually requires clinical information, radiographical images, and histological findings, 
but sometimes it can be challenging. In many cases, it can be difficult or impossible to distinguish FD from 
other fibro-osseous lesions only based on histological findings. Several studies reported that GNAS mutation 
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was absent in other fibro-osseous disorders such as low-grade osteosarcoma, ossifying fibroma, and osteofibrous 
dysplasia, and therefore GNAS gene analysis can aid the differntiation of FD from such disease entities15, 16, 26.
A previous meta-analysis reported that the detection rate of GNAS mutation varied from 45–95%15–19, and the 
overall positive detection rate of GNAS mutation was 71.9% in 203 patients with FD14. In our study, pyrosequenc-
ing results detected GNAS mutations in only 32.2% of FD cases, regardless of decalcification. This result might be 
explained by differences in methodologies used to detect GNAS mutations, which result in different sensitivities. 
Several methods for detecting mutations have been published, including direct sequencing7, mutation-specific 
restriction enzyme digestion13, 26, PCR coupled with allele-specific oligonucleotide hybridization6, PCR–restric-
tion fragment length polymorphism27, PCR with peptide nucleic acid28, and PCR with pyrosequencing19. A pre-
vious study performed pyrosequencing and reported the detection of GNAS mutations in 95% of FD patients, 
which is a much higher detection rate than that observed in the present study.
Next, we evaluated the effect of tissue decalcification on the detection of GNAS mutations in patients with 
FD. Many standard protocols for preparing bony tissue samples include treatment with strong acid to decalcify 
the tissue before fixation and embedding. This harsh treatment may affect the integrity of DNA isolated from the 
tissue, and thereby reduce the quantity and quality of DNA for PCR amplification and sequencing21. In this study, 
Figure 1. Histological features of fibrous dysplasia, which contains fibrous tissue with irregular, curvilinear, 
and trabeculae of woven bone in varying proportions. (A) Low fibrous tissue. (B) Abundant fibrous tissue. (C) 
Typical irregularly shape woven bones without osteoblastic rimming were observed in most cases. Some cases 
showed (D) aggregation of foamy histiocytes and (E) cystic changes. (F) Benign cartilaginous differentiation 
was observed in one case.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 2836  | DOI:10.1038/s41598-017-03093-1
specimens were decalcified with Calci-Clear Rapid solution for 24 hours. The detection rate of GNAS mutations 
was 9.6% (5/52) in decalcified specimens and 65.7% (23/35) in non-decalcified specimens. A comparison of the 
detection rates of GNAS mutations in FD samples from 15 FD patients that were either decalcified or undercal-
cified also indicated that the detection rate of GNAS mutation was much higher in undercalcified tissues (9/15, 
60.0%) than in decalcified tissues (2/15, 13.3%, p = 0.021).
The present study showed that patients with polyostotic FD more frequently displayed p.R201H mutation in 
GNAS than patients with monostotic FD (p = 0.077). This result was not consistent with a previous report that 
patients with polyostotic FD had R201C mutation in GNAS29. We identified p.R201C mutation in one of seven 
patients with polyostotic FD. The lack of statistical significance in our result may be due to the small number of 
cases in our study.
GNAS mutations status Cysteine or histidine substitution
Absence of 
mutation 















 Female 30 (50.8%) 14 (50.0%) 6 (42.9%) 8 (57.1%)
 Male 29 (49.2%) 14 (50.0%) 8 (57.1%) 6 (42.9%)
Age at diagnosis, 
Mean ± S.D.(year) 31.5 ± 2.279 30.1 ± 3.035 0.718 27.86 ± 4.436 32.29 ± 4.224 0.476
Lesion site 0.099 0.663
 Craniofacial 27 (45.8%) 7 (25.0%) 4 (28.6%) 3 (21.4%)
 Extra-craniofacial 32 (54.2%) 21 (75.0%) 10 (71.4%) 11 (78.6%)
Multiplicity 0.011 0.077
 Monostotic 56 (94.9%) 21 (75.0%) 13 (92.9%) 8 (57.1%)
 Polyostotic 3 (5.1%) 7 (25.0%) 1 (7.1%) 6 (42.9%)
Decalcification 0.001 0.326
 No 12 (20.3%) 23 (82.1%) 10 (71.4%) 13 (92.9%)
 Yes 47 (79.7%) 5 (17.9%) 4 (28.6%) 1 (7.1%)
Table 1. Clinical findings in fibrous dysplasia patients according to GNAS mutations status and cysteine or 
histidine substitution.
Figure 2. Typical pyrogram of (A) wild-type, (B) R201H (CGT → CAT), and (C) R201C (CGT → TGT) 
mutations of GNAS in fibrous dysplasia.
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In this study, we demonstrated that GNAS mutations were more frequently detected in FD tissue samples 
without decalcification than in decalcified FD tissue samples. And, most of the polyostotic FD patients displayed 
R201H substitution mutation in GNAS. Therefore, GNAS mutation test should be conducted without performing 
decalcification. Also, if sequencing analysis detects an R201H mutation in GNAS, we suggest that the clinician 
should consider the possibility of polyostotic FD.
Materials and Methods
Patients and samples. We retrospectively recruited 93 patients who were diagnosed with FD at Severance 
Hospital, Yonsei University College of Medicine, from 2006 to 2016. A total of 107 tissue samples were collected. 
The specimens included 72 decalcified FFPE specimens and 35 non-decalcified FFPE specimens. The DNA iso-
lated from six patients was not suitable for molecular studies; therefore, we analyzed the DNA of 87 patients with 
FD. Ten patients presented with multiple bone lesions on radiological studies when FD was initially diagnosed, 
suggesting polyostotic FD. Among the ten polyostotic patients, only two patients underwent multiple biopsies 
and/or curettages from different locations, whereas the other patients received only one biopsy or curettage from 
a representative lesion. In 15 cases, only part of the specimen was subjected to decalcification and the rest was not 
decalcified, which enabled a direct comparison of the effect of decalcification on the detection of mutations in a 
tissue specimen. For decalcification, the tissue samples were decalcified with Calci-Clear Rapid solution contain-
ing EDTA and hydrochloric acid (National Diagnostics, Georgia, USA) for 24 hours, fixed in 10% formalin, and 
then embedded in paraffin.
To select the most representative FFPE tissues for molecular studies, samples were mounted on slides, stained 
with hematoxylin and eosin (H&E), and reviewed by two pathologists (SJS and SKK). Medical records were 
reviewed for clinical features, and radiological and pathological findings.
All methods and experimental protocols using human tissue (FFPE tissue) were carried out in accordance 
with relevant guidelines and regulations approved by the Institutional Review Board of Severance Hospital, 
Yonsei University Health System (4-2016-0276). The informed consent was waved because the IRB decided that 
this retrospective study had a minimal risk to the patients (risk level I).
DNA extraction and PCR amplification. Genomic DNA was extracted from 10 μm sections cut from 
FFPE tissue blocks using the Maxwell® CSC DNA FFPE extraction kit (Promega, Wisconsin, USA) and the 
Maxwell® CSC instrument. The genomic DNA was subjected to PCR amplification optimized for pyrosequenc-
ing analysis; reactions contained 9 μl (10 ng/μl) of DNA, 12.5 μl of 2 × PyroMark PCR master mix (QIAGEN, 
Hilden, Germany), 2.5 μl of 10x CoralLoad PCR loading buffer (QIAGEN), and 1 μl each of the forward and 
reverse primers, in a total reaction volume of 25 μl (Supplementary Table 2). The following program was used for 
PCR amplification: 95 °C for 15 minutes; followed by 45 cycles of 94 °C for 30 seconds, 59 °C for 30 seconds, and 
72 °C for 30 seconds; and a final extension step of 72 °C for 10 minutes.
Pyrosequencing. After PCR analysis, single-stranded DNA suitable for pyrosequencing was prepared using 
the PyroMark Q24 MDx Vacuum Workstation (QIAGEN, Hilden, Germany). In workstation, the biotinylated 
PCR products were bound to streptavidin-coated sepharose beads. The beads were released into a PyroMark 
Q24 Plate containing 25 μl of annealing buffer and 0.3 μM of sequencing primer. The sample was heated to 80 °C 
for 2 minutes, and then cooled to room temperature. Pyrosequencing was performed in a PyroMark Q24 MDx 
(QIAGEN) according to the manufacturer’s instructions. Sequencing data were analyzed using PyroMark Q24 
MDx Software 2.0 (QIAGEN).
Statistical analysis. All statistical analyses were performed using SPSS version 18.0 (IBM, Chicago, 
IL, USA). The relationships between groups were compared using the χ2 test, Fisher’s exact test, or the 
Mann-Whitney U-test. Two-sided P values < 0.05 were considered as statistically significant.
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